公开(公告)号：US20240239880A1

公开(公告)日：2024-07-18

申请号：US18609247

申请日：2024-03-19

Applicant: H. LUNDBECK A/S

Inventor： Roger K. Cady ,  Jeffrey T.L. Smith ,  Joseph Hirman ,  Barbara Schaeffler ,  Lahar Mehta

IPC: C07K16/18 ,  A61K9/00 ,  A61K31/4172 ,  A61K39/395 ,  A61K45/06 ,  A61K47/26 ,  A61P25/06 ,  A61K38/00 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K9/0019 ,  A61K31/4172 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/26 ,  A61P25/06 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24

Abstract: Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.

公开(公告)号：US12018004B2

公开(公告)日：2024-06-25

申请号：US18053582

申请日：2022-11-08

Applicant: H. Lundbeck A/S ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Justin S. Cisar ,  Cheryl A. Grice ,  Todd K. Jones ,  Micah J. Niphakis ,  Jae Won Chang ,  Kenneth M. Lum ,  Benjamin F. Cravatt

IPC: C07D295/205 ,  A61P25/22 ,  C07C271/10 ,  C07C271/12 ,  C07D205/04 ,  C07D207/09 ,  C07D207/14 ,  C07D213/38 ,  C07D213/40 ,  C07D213/55 ,  C07D215/42 ,  C07D215/46 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D241/04 ,  C07D261/08 ,  C07D263/32 ,  C07D271/06 ,  C07D295/26 ,  C07D307/79 ,  C07D317/46 ,  C07D317/58 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10 ,  C07D405/14 ,  C07D407/06 ,  C07D413/06 ,  C07D413/10 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107

CPC classification number: C07D295/205 ,  A61P25/22 ,  C07C271/10 ,  C07C271/12 ,  C07D205/04 ,  C07D207/09 ,  C07D207/14 ,  C07D213/38 ,  C07D213/40 ,  C07D213/55 ,  C07D215/42 ,  C07D215/46 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D241/04 ,  C07D261/08 ,  C07D263/32 ,  C07D271/06 ,  C07D295/26 ,  C07D307/79 ,  C07D317/46 ,  C07D317/58 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10 ,  C07D405/14 ,  C07D407/06 ,  C07D413/06 ,  C07D413/10 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107

Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.

公开(公告)号：US20240190909A1

公开(公告)日：2024-06-13

申请号：US18511231

申请日：2023-11-16

Applicant: H. Lundbeck A/S

Inventor： Klaus Gjervig Jensen ,  Lisbet Kværnø ,  Morten Jørgensen ,  Martin Juhl ,  Heidi Lopez De Diego ,  Karin Fredholt ,  Frans Dennis Therkelsen ,  Tobias Gylling Frihed ,  Mikkel Fog Jacobsen

IPC: C07H15/26

CPC classification number: C07H15/26 ,  C07B2200/13

Abstract: The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below.




The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.

公开(公告)号：US11993612B2

公开(公告)日：2024-05-28

申请号：US18331289

申请日：2023-06-08

Applicant: H. Lundbeck A/S

Inventor： Thomas Jensen ,  Mikkel Jessing ,  Wanwan Yu ,  David Rodriguez Diaz ,  Jacob Nielsen ,  Christopher Richard Jones ,  Thomas Andersen ,  Mikkel Fog Jacobsen

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07B2200/05

Abstract: The present invention is directed to compounds of formula I




The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.

公开(公告)号：US11938185B2

公开(公告)日：2024-03-26

申请号：US17122243

申请日：2020-12-15

Applicant: H. LUNDBECK A/S

Inventor： Maria-Cristina Loomis ,  Leon F. Garcia-Martinez ,  Benjamin H. Dutzar ,  Daniel S. Allison ,  Katherine Lee Hendrix ,  Ethan W. Ojala ,  Pei Fan ,  Jeffrey T. L. Smith ,  John A. Latham ,  Charlie Karasek ,  Jenny Mulligan ,  Michelle Scalley-Kim ,  Erica Stewart ,  Vanessa Lisbeth Rubin ,  Jens J. Billgren

IPC: A61K39/395 ,  A61P9/08 ,  A61P25/06 ,  C07K14/705 ,  C07K14/72 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/42 ,  C12N5/07 ,  C12N15/09 ,  C12N15/63 ,  G01N33/68 ,  A61K38/00 ,  A61K38/17 ,  A61K38/22 ,  A61K39/00 ,  A61K48/00 ,  C07K14/47 ,  C07K14/575

CPC classification number: A61K39/3955 ,  A61P9/08 ,  A61P25/06 ,  C07K14/70503 ,  C07K14/72 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2869 ,  C07K16/4241 ,  C12N5/06 ,  C12N15/09 ,  C12N15/63 ,  G01N33/6854 ,  A61K38/00 ,  A61K38/17 ,  A61K38/22 ,  A61K2039/505 ,  A61K48/00 ,  C07K14/47 ,  C07K14/575 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/575 ,  Y02A50/30

Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

公开(公告)号：US20240067708A1

公开(公告)日：2024-02-29

申请号：US18173124

申请日：2023-02-23

Applicant: H. Lundbeck A/S

Inventor： Roger K. Cady ,  Jeffrey T.L. Smith ,  Joseph Hirman ,  Barbara Schaeffler ,  Lahar Mehta

IPC: C07K16/18 ,  A61K9/00 ,  A61K31/4172 ,  A61K39/395 ,  A61K45/06 ,  A61K47/26 ,  A61P25/06

CPC classification number: C07K16/18 ,  A61K9/0019 ,  A61K31/4172 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/26 ,  A61P25/06 ,  A61K2039/505

Abstract: Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.

公开(公告)号：US20240025979A1

公开(公告)日：2024-01-25

申请号：US18341437

申请日：2023-06-26

Applicant: H. Lundbeck A/S

Inventor： Josefine NIELSEN SØDERBERG ,  Pekka Kallunki ,  Louise Buur ,  Frank Larsen ,  Henrik Rajesh Kumar Parshad ,  Anne Sofie Markussen ,  Mark Cornell Manning ,  Derrick Spencer Katayama ,  Magdalena Gauden ,  John Smith

IPC: C07K16/18 ,  A61K39/395 ,  A61K47/22 ,  A61K47/26

CPC classification number: C07K16/18 ,  A61K39/39591 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/545

Abstract: The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and/or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.

公开(公告)号：US20230265095A1

公开(公告)日：2023-08-24

申请号：US18051654

申请日：2022-11-01

Applicant: H. Lundbeck A/S

Inventor： Thomas VETTER ,  Martin JUHL ,  HEIDI LOPEZ DE DIEGO ,  Cheryl A. GRICE ,  John J.M. WIENER ,  Daniel J. BUZARD ,  Amy ALLAN ,  Susana DEL RIO GANCEDO ,  Samuel George ANDREW ,  Antonio CINCOTTI ,  Adam Ross PATTERSON ,  Richard James EDWARDS

IPC: C07D471/10

CPC classification number: C07D471/10 ,  C07B2200/13

Abstract: Described herein are new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)b enzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230174641A1

公开(公告)日：2023-06-08

申请号：US17850135

申请日：2022-06-27

Applicant: H. LUNDBECK A/S.

Inventor： Andrew Lawrence FELDHAUS ,  Leon GARCIA-MARTINEZ ,  Benjamin H. DUTZAR ,  Daniel S. ALLISON ,  Katie Olson ANDERSON ,  Ethan Wayne OJALA ,  Pei FAN ,  Charlie KARASEK ,  Jenny MULLIGAN ,  Michelle SCALLEY-KIM ,  Erica STEWART ,  Jeffrey T.L. SMITH ,  John LATHAM

IPC: C07K16/26

CPC classification number: C07K16/26 ,  C07K2317/34 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/92 ,  C07K2317/76 ,  A61K2039/505

Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-ACTH antibodies and binding fragments thereof for the diagnosis, assessment, prevention and treatment of diseases and disorders associated with ACTH, such as Cushing's Disease, Cushing's Syndrome, Parkinson's disease, obesity, diabetes, sleep disorders depression, anxiety disorders, cancer, muscle atrophy, hypertension, hyperinsulinemia, cognitive dysfunction, Alzheimer's disease, galactorrhea, stress related conditions, cardiac conditions, metabolic syndrome, hyperaldosteronism, Conn's syndrome and familial hyperaldosteronism.

公开(公告)号：US11639380B2

公开(公告)日：2023-05-02

申请号：US16736925

申请日：2020-01-08

Applicant: H. LUNDBECK A/S

Inventor： Roger K. Cady ,  Jeffrey T. L. Smith ,  Joseph Hirman ,  Barbara Schaeffler ,  Lahar Mehta

IPC: C07K16/18 ,  A61K9/00 ,  A61K39/395 ,  A61K31/4172 ,  A61K47/26 ,  A61K38/00 ,  A61P25/06 ,  A61K45/06 ,  A61K39/00

Abstract: Methods for rapid treatment of chronic migraine are provided. Exemplary methods provide relief from migraine within 24 hours of administration. Also provided are methods for acute treatment of migraine. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.